-
1.发明公开Therapeutic application of chimeric antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma 失效嵌合的和标记的抗体的治疗用途其针对一个分化抗原，其表达仅限于人B淋巴细胞为B细胞淋巴瘤的治疗
公开(公告)号：EP1005870A2
公开(公告)日：2000-06-07
申请号：EP99123967.4
申请日：1993-11-12
发明人： Anderson, Darrell R. , Hanna, Nabil , Leonard, John E. , Newman, Roland A. , Reff, Mitchell E. , Rastetter, William H.
CPC分类号： C07K16/2887 , A61K38/00 , A61K47/6849 , A61K51/1027 , A61K51/1093 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/732 , C07K2319/00 , C12N2799/028 , Y10S424/80 , Y10S424/801 , Y10S530/808 , Y10S530/809 , Y10S530/867
摘要： Disclosed herein is an immunologically active, chimeric anti-CD20 antibody for use as a medicament, which antibody is capable of substantial B-cell depletion when administered to a subject.
摘要翻译： 公开在是用作药物，所述抗体能够大幅B细胞耗竭当施用给受试者的免疫活性的，嵌合的抗CD20抗体。
-
2.发明公开Therapeutic application of chimeric antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma 失效嵌合的和标记的抗体的治疗用途其针对一个分化抗原，其表达仅限于人B淋巴细胞为B细胞淋巴瘤的治疗
公开(公告)号：EP1005870A3
公开(公告)日：2002-10-23
申请号：EP99123967.4
申请日：1993-11-12
发明人： Anderson, Darrell R. , Hanna, Nabil , Leonard, John E. , Newman, Roland A. , Reff, Mitchell E. , Rastetter, William H.
IPC分类号： A61K39/395 , A61K51/10 , C12N15/02 , C12P21/08 , C07K16/46
CPC分类号： C07K16/2887 , A61K38/00 , A61K47/6849 , A61K51/1027 , A61K51/1093 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/732 , C07K2319/00 , C12N2799/028 , Y10S424/80 , Y10S424/801 , Y10S530/808 , Y10S530/809 , Y10S530/867
摘要： Disclosed herein is an immunologically active, chimeric anti-CD20 antibody for use as a medicament, which antibody is capable of substantial B-cell depletion when administered to a subject.
摘要翻译： 在治疗性治疗方案被设计用于B细胞淋巴瘤的公开的治疗。 这些协议是基于治疗策略，包括使用免疫活性鼠/人嵌合抗CD20抗体，放射性标记的抗CD20抗体，合作策略，包括使用嵌合抗CD20抗体和放射性标记的抗CD20抗体的管理。
-
3.发明授权Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma 失效嵌合的和标记的抗体的治疗用途其针对一个分化抗原，其表达仅限于人B淋巴细胞，B细胞淋巴瘤的治疗
公开(公告)号：EP0752248B1
公开(公告)日：2000-09-27
申请号：EP96200772.0
申请日：1993-11-12
发明人： Anderson, Darrell R. , Hanna, Nabil , Leonard, John E. , Newman, Roland A. , Reff, Mitchell E. , Rastetter, William H.
IPC分类号： A61K39/395 , A61K51/10 , C12N15/02 , C12P21/08 , C07K16/46
CPC分类号： C07K16/2887 , A61K38/00 , A61K47/6849 , A61K51/1027 , A61K51/1093 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/732 , C07K2319/00 , C12N2799/028 , Y10S424/80 , Y10S424/801 , Y10S530/808 , Y10S530/809 , Y10S530/867
-
4.发明公开Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma 失效嵌合的和标记的抗体的治疗用途对男子工会B淋巴细胞限制性分化抗原用于治疗B细胞淋巴瘤的
公开(公告)号：EP0752248A1
公开(公告)日：1997-01-08
申请号：EP96200772.0
申请日：1993-11-12
发明人： Anderson, Darrell R. , Hanna, Nabil , Leonard, John E. , Newman, Roland A. , Reff, Mitchell E. , Rastetter, William H.
CPC分类号： C07K16/2887 , A61K38/00 , A61K47/6849 , A61K51/1027 , A61K51/1093 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/732 , C07K2319/00 , C12N2799/028 , Y10S424/80 , Y10S424/801 , Y10S530/808 , Y10S530/809 , Y10S530/867
摘要： Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, and cooperative strategies comprising the use of chimeric anti-CD20 antibodies and radiolabeled anti-CD20 antibodies.
摘要翻译： 在治疗性治疗方案被设计用于B细胞淋巴瘤的公开的治疗。 这些协议是基于治疗策略，包括使用免疫活性鼠/人嵌合抗CD20抗体，放射性标记的抗CD20抗体，合作策略，包括使用嵌合抗CD20抗体和放射性标记的抗CD20抗体的管理。
-
-
-
搜索结果
4 条记录 (耗时 0.013 秒)
